A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued?
暂无分享,去创建一个
G. Fabbrocini | M. Megna | L. Costanzo | L. Gallo | A. Ruggiero | V. Marino | S. Ocampo-Garza | Chiara Miano
[1] G. Fabbrocini,et al. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐interleukin‐17 treatment: A real‐life 52‐week retrospective study , 2020, Dermatologic therapy.
[2] G. Fabbrocini,et al. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience , 2020, The Journal of dermatological treatment.
[3] G. Fabbrocini,et al. Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa , 2020, Dermatologic therapy.
[4] G. Fabbrocini,et al. A case of severe psoriasis in a 84‐year‐old women successfully treated with ixekizumab , 2020, Dermatologic therapy.
[5] G. Fabbrocini,et al. A case of erythrodermic psoriasis successfully treated with guselkumab , 2019, Dermatologic therapy.
[6] B. Strober,et al. Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis , 2017, The British journal of dermatology.
[7] T. Chiller,et al. Fungal Infections and New Biologic Therapies , 2016, Current Rheumatology Reports.
[8] M. Lebwohl,et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials , 2015, The Lancet.
[9] A. Puel,et al. IL-17 and infections. , 2014, Actas dermo-sifiliograficas.
[10] H. Kang,et al. Prevalence and Risk Factors of Esophageal Candidiasis in Healthy Individuals: A Single Center Experience in Korea , 2012, Yonsei medical journal.